{"id":"jskn003","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"JSKN003 functions as a bispecific antibody designed to target multiple immune regulatory pathways. By engaging dual immune checkpoints, it aims to overcome tumor immune evasion mechanisms and potentiate T cell-mediated anti-tumor immunity more effectively than single-target checkpoint inhibitors.","oneSentence":"JSKN003 is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T cell responses.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:17:43.119Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced solid tumors (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT07384377","phase":"PHASE3","title":"JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan","status":"NOT_YET_RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2026-02-06","conditions":"HER2-positive Colorectal Cancer","enrollment":123},{"nctId":"NCT05744427","phase":"PHASE1, PHASE2","title":"Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","startDate":"2023-03-15","conditions":"Advanced Solid Tumor","enrollment":725},{"nctId":"NCT07283198","phase":"PHASE2","title":"A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","startDate":"2025-12-10","conditions":"Non Small Cell Lung Cancer (NSCLC)","enrollment":160},{"nctId":"NCT06079983","phase":"PHASE3","title":"JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects","status":"RECRUITING","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","startDate":"2023-12-01","conditions":"Breast Cancer","enrollment":400},{"nctId":"NCT06226766","phase":"PHASE1, PHASE2","title":"JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors","status":"TERMINATED","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","startDate":"2024-01-18","conditions":"Advanced Solid Tumor","enrollment":11},{"nctId":"NCT05494918","phase":"PHASE1","title":"First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors","status":"COMPLETED","sponsor":"Alphamab (Australia) Co Pty Ltd.","startDate":"2022-09-02","conditions":"Advanced Solid Tumors, Metastatic Solid Tumors","enrollment":62},{"nctId":"NCT05582499","phase":"PHASE2","title":"Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-11-01","conditions":"Breast Neoplasm, Breast Cancer, Breast Tumors","enrollment":716},{"nctId":"NCT06998771","phase":"PHASE2","title":"JSKN003 Combined Treatment of HER2-positive Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2025-06-15","conditions":"HER2-positive Gastric Cancer","enrollment":153},{"nctId":"NCT06846437","phase":"PHASE3","title":"JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer","status":"RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2025-02-18","conditions":"Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants","enrollment":228},{"nctId":"NCT06751485","phase":"PHASE3","title":"JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","startDate":"2025-01-15","conditions":"Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancers","enrollment":430}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["anti-Her2 ADC JSKN003"],"phase":"phase_3","status":"active","brandName":"JSKN003","genericName":"JSKN003","companyName":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","companyId":"jiangsu-alphamab-biopharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"JSKN003 is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T cell responses. Used for Advanced solid tumors (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}